Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain

Calleja, Miguel Ángel; Navarro, Andrés; Serratosa, José M.; Toledo, Manuel; Villanueva, Vicente; Labazuy, Silvia Subías; Gil, Alicia

doi:10.1080/14737167.2022.2107507

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies in Spain and UK showed cost-effectiveness of cenobamate compared to third-generation ASMs, due in the UK study to greater seizure frequency reduction with cenobamate relative to comparators." [37][38][39] We are not aware of US studies comparing the cost-effectiveness of cenobamate or fenfluramine. These would be useful.…”

Section: Restrictionmentioning

confidence: 99%

“…Its cost is similar to other new branded ASMs approved since 2009 (see Table 1 and https://www.wolterskluwer.com/en/solutions/medi-span/price-rx 36 for cost of recently approved ASMs in the United States and Table 2 for prices in Germany) and its use may reduce health care cost overall by increasing rates of seizure freedom or near‐freedom (90% reduction) and reducing ER visits, hospitalizations, intensive care unit (ICU) admissions, and office visits. Recent studies in Spain and UK showed cost‐effectiveness of cenobamate compared to third‐generation ASMs, due in the UK study to greater seizure frequency reduction with cenobamate relative to comparators.” 37–39 We are not aware of US studies comparing the cost‐effectiveness of cenobamate or fenfluramine. These would be useful.…”

Section: Access To Care Restrictionmentioning

confidence: 99%

See 1 more Smart Citation

Failure to use new breakthrough treatments for epilepsy

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Restrictionmentioning

confidence: 99%

Section: Access To Care Restrictionmentioning

confidence: 99%

Failure to use new breakthrough treatments for epilepsy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Thus, CNB can produce more health per invested euro. Calleja et al, suggested that CNB therapy can produce an incremental clinical benefit over third-generation ASMs [ 102 ].…”

Section: Discussionmentioning

confidence: 99%

Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature

Rissardo,

Fornari Caprara

2023

Medicina

View full text Add to dashboard Cite

Cenobamate (CNB), ([(R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl], is a novel tetrazole alkyl carbamate derivative. In November 2019, the Food and Drug Administration approved Xcopri®, marketed by SK Life Science Inc., (Paramus, NJ, USA) for adult focal seizures. The European Medicines Agency approved Ontozry® by Arvelle Therapeutics Netherlands B.V.(Amsterdam, The Neatherlands) in March 2021. Cenobamate is a medication that could potentially change the perspectives regarding the management and prognosis of refractory epilepsy. In this way, this study aims to review the literature on CNB’s pharmacological properties, pharmacokinetics, efficacy, and safety. CNB is a highly effective drug in managing focal onset seizures, with more than twenty percent of individuals with drug-resistant epilepsy achieving seizure freedom. This finding is remarkable in the antiseizure medication literature. The mechanism of action of CNB is still poorly understood, but it is associated with transient and persistent sodium currents and GABAergic neurotransmission. In animal studies, CNB showed sustained efficacy and potency in the 6 Hz test regardless of the stimulus intensity. CNB was revealed to be the most cost-effective drug among different third-generation antiseizure medications. Also, CNB could have neuroprotective effects. However, there are still concerns regarding its potential for abuse and suicidality risk, which future studies should clearly assess, after which protocols should be changed. The major drawback of CNB therapy is the slow and complex titration and maintenance phases preventing the wide use of this new agent in clinical practice.

show abstract